<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="case-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Case Rep Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Case Rep Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">CRIPS</journal-id>
<journal-title-group>
<journal-title>Case Reports in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">2090-682X</issn>
<issn pub-type="epub">2090-6838</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32089936</article-id>
<article-id pub-id-type="pmc">7011498</article-id>
<article-id pub-id-type="doi">10.1155/2019/4764031</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Case Series</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Clinical Management of Children and Adolescents with Neurofibromatosis Type 1 Like Phenotypes and Complex Behavioural Manifestations: A Multidisciplinary and Dimensional Approach</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-6277-5616</contrib-id>
<name>
<surname>Moscoso</surname>
<given-names>Ana</given-names>
</name>
<email>anamoscoso@yahoo.com</email>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Julien</surname>
<given-names>Aurélie</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tanet</surname>
<given-names>Antoine</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Consoli</surname>
<given-names>Angèle</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pagnard</surname>
<given-names>Martine</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trevisan</surname>
<given-names>France</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kemlin</surname>
<given-names>Isabelle</given-names>
</name>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rodriguez</surname>
<given-names>Diana</given-names>
</name>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cohen</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Department of Child and Adolescent Psychiatry, Robert Debré Hospital, Paris, France</aff>
<aff id="I2">
<sup>2</sup>Department of Child and Adolescent Psychiatry, Reference Center for Rare Psychiatric Diseases, APHP, Groupe Hospitalier Pitié-Salpêtrière, Université Sorbonne, Paris, France</aff>
<aff id="I3">
<sup>3</sup>GRC-15, Approche Dimensionnelle des Épisodes Psychotiques de L'enfant et de L'adolescent, Faculté de Médecine, UPMC, Sorbonne Universités, Paris, France</aff>
<aff id="I4">
<sup>4</sup>Centre de Référence des Neurofibromatoses et Service de Neurologie Pédiatrique, AP-HP, Hôpital Armand Trousseau, GHUEP, Paris, France</aff>
<aff id="I5">
<sup>5</sup>Sorbonne Université, Hôpital Armand Trousseau, F-75012, Paris, France</aff>
<aff id="I6">
<sup>6</sup>Institut des Systèmes Intelligents et Robotiques, CNRS, UMR 7222, Université Sorbonne, Paris, France</aff>
<author-notes>
<fn fn-type="other">
<p>Academic Editor: Erik Jönsson</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>2019</volume>
<elocation-id>4764031</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Ana Moscoso et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>
<italic>Introduction.</italic> Cognitive and behavioural problems associated with Neurofibromatosis type 1 (NF1) are common sources of distress and the reasons behind seeking help. Here we describe patients with NF1 or NF1-like phenotypes referred to a Tier 3 Child and Adolescent Psychiatry Department and highlight the benefits of a multidisciplinary assessment. </p>
<sec>
<title>Methods</title>
<p>Prospective data were gathered from NF1 patients aged 7–15 years, referred by the NF1 Referral Centre due to additional difficulties either in management or diagnosis. For the selected cases, we performed a psychiatric assessment, a tailored neuropsychological evaluation based on clinical demands and history, broad speech and motor skills evaluations if there were concerns regarding language, motor abilities and/or learning difficulties and autism specific evaluations, if clinically relevant. No exclusion criteria were applied. </p>
</sec>
<sec>
<title>Results</title>
<p>Complex NF1 cases represented only 5% of the patients (11/224). Assessments revealed the complexity of NF1 phenotype and a variety of problems including learning difficulties, emotional problems and autism spectrum disorders. Specific evaluations of language, motor, attentional and neurovisual domains were essential to guide tailored intervention strategies. </p>
</sec>
<sec>
<title>Conclusions</title>
<p>In terms of clinical implications, the heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with complex NF1.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. Background</title>
<p>Neurofibromatosis type 1 (NF1) affects approximately 1/3,000 individuals worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. Diagnostic criteria are varied and include <italic>café-au-lait</italic> spots, neurofibromas, freckling of the axillary or inguinal regions, optic glioma, Lisch nodules, distinctive osseous lesions (such as sphenoid dysplasia or thinning of long bone cortex), as well as having a first-degree relative evidencing NF1 symptoms as detailed above [<xref ref-type="bibr" rid="B2">2</xref>].</p>
<p>Although NF1 is an autosomal dominant condition (familiar type), de novo mutations account for up to 50% of the cases (sporadic type). <italic>NF1</italic> is completely penetrant, nonetheless it exhibits variable clinical expressivity, even between family members with the same <italic>NF1</italic> mutation [<xref ref-type="bibr" rid="B3">3</xref>]. Most <italic>NF1</italic> mutations result in reduced intracellular levels of the protein neurofibromin, leading to excessive cell proliferation, including development of neurofibromas and tumours and diminished cognitive capacity [<xref ref-type="bibr" rid="B4">4</xref>].</p>
<p>In clinical practice, cognitive and behavioural problems associated with NF1 and their impact on academic performance is a common source of distress and the reason behind seeking help in child psychiatry. Indeed, between 30% and 70% of individuals with NF1 have learning disabilities concerning speech, reading, writing, spelling and mathematics. These problems represent the most significant cause of lifetime morbidity associated with the disease [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>]. Even though some phenotypic patterns have been suggested in the past, a more in-depth analysis reinforces the need to tailor the diagnosis and the treatment of these patients.</p>
<p>The global cognitive functioning of NF1 patients is usually preserved, although somewhat lower when compared to unaffected siblings or peer groups [<xref ref-type="bibr" rid="B7">7</xref>]. Intellectual disability, defined clinically as an intelligence quotient (IQ) lower than 70 in cognitive evaluations, is estimated to be around 4–8% in NF1 patients vs. 2-3% in the general population [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>]. However, the exclusion of patients with central nervous system (CNS) pathology from cohort studies of NF1 prevalence reduces the number of patients with clinically moderate to severe NF1 [<xref ref-type="bibr" rid="B8">8</xref>] and may underestimate the prevalence of intellectual disability amongst this population.</p>
<p>For many years the Child and Adolescent Psychiatry Department of Pitié-Salpêtrière has been treating paediatric patients who present neuropsychiatric symptoms of rare diseases [<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B12">12</xref>] as examples. As a specialised team, the department receives complex patients which present significant management issues. NF1 patients are referred to this department. Here we describe patients with NF1 received in our Departement and highlight the benefits of a multidisciplinary assessment.</p>
</sec>
<sec id="sec2">
<title>2. Methods</title>
<sec id="sec2.1">
<title>2.1. Patients</title>
<p>Prospective data were gathered from NF1 patients (NIH, 1988) aged 7–15 years, referred by the Neurofibromatosis Referral Centre at Trousseau Paediatric Hospital for evaluation at the Department of Child and Adolescent Psychiatry at University Hospital La Pitié-Salpêtrière. The data spans from 2009 until 2016. The procedures regarding the assessments and follow-ups at the Referral Centre are described elsewhere [<xref ref-type="bibr" rid="B13">13</xref>]. Referrals were made due to additional difficulties either in management or diagnosis of patients and represented only a small part of the cohort (11/224—approximately 5%). No exclusion criteria were applied as we wanted to describe all complex aspects of this clinical sub sample.</p>
</sec>
<sec id="sec2.2">
<title>2.2. Procedures and Instruments</title>
<p>Patients were assessed in medical consultations and further comprehensive evaluations. For the selected cases, we extracted from the prospective database: sociodemographic data (age, sex, academic level); all relevant information from the semi-structured medical interview to evaluate the patient's personality and family history of psychiatric and medical disorders, including NF1 clinical features, complications and follow-ups; and all relevant biological (e.g. genetic testing), physiological (e.g. electro-encephalography) and imaging (e.g. magnetic resonance imaging) information. In addition, we performed (1) a psychiatric assessment; (2) a tailored neuropsychological evaluation (e.g. executive function, attention, memory, neurovisual) based on clinical demands and history; (3) a broad speech evaluation, if there were language (oral and/or written) concerns or learning difficulties; (4) a global and fine motor skills evaluation, if there were concerns regarding motor abilities and/or learning difficulties (such as difficulties to write), and (5) autism specific evaluations, if clinically relevant. The list of testing is given in Tables <xref ref-type="table" rid="tab1">1</xref> and <xref ref-type="table" rid="tab2">2</xref>.</p>
<p>Evaluations were performed because they had clinical relevance. They were adapted to the needs and characteristics of each patient. Medical files containing clinical data were thoroughly explored (AM, AJ, MP) and relevant data were included (AM, AJ, AT, MP). Psychiatric diagnoses were made according to DSM-5 criteria. Finally, the scores obtained in neuropsychological, speech and fine motor skills assessments were converted into standard deviations in order to have unique common statistics and to ease presentation.</p>
</sec>
</sec>
<sec id="sec3">
<title>3. Results</title>
<p>Eleven patients were included. All, except one, were boys with a mean age of 10.6 (range 7–15) years. Five patients had a first degree relative with NF1 (father, mother or sibling). Two patients lived in foster care and five with one parent (due to divorce). One had Legius syndrome, a genetic condition associated with <italic>sprouty related EVH1 domain containing 1 (SPREAD1) </italic>gene mutation, which phenotype overlaps that of NF1 [<xref ref-type="bibr" rid="B14">14</xref>]. For clarity, we present the patients in two separate tables. <xref ref-type="table" rid="tab1"> Table 1</xref> summarises the clinical profile of four NF1 patients with an intellectual deficiency and <xref ref-type="table" rid="tab2">Table 2</xref> presents the profile of patients with subnormal IQ.</p>
<sec id="sec3.1">
<title>3.1. Reasons for Referral</title>
<p>Patients came with multiple and diverse complaints. Reasons for referral included learning difficulties (due to the consequences of instrumental difficulties, suspicion of attention deficit hyperactivity disorder (ADHD) or intellectual disability; <italic>N</italic> = 7), or emotional problems or suspicion of emergent psychopathology (<italic>N</italic> = 6). A few (<italic>N</italic> = 4) were referred because of autism spectrum disorder (ASD) (doubts regarding diagnosis or difficulties in clinical management).</p>
</sec>
<sec id="sec3.2">
<title>3.2. NF1 Clinical Characteristics and Intellectual Impairment</title>
<p>Clinical complications of NF1 (skeletal, vascular, malignancy, epilepsy, precocious puberty, the presence of unidentified bright objects (UBOs) in CNS) were present in patients who also had a certain degree of intellectual disability (<xref ref-type="table" rid="tab1">Table 1</xref>), sometimes accompanied by autistic features (patients 1, 2, 4; <xref ref-type="table" rid="tab1">Table 1</xref>). Only, one patient with NF1 complications did not present with an intellectual disability but had a borderline IQ (patient 8; <xref ref-type="table" rid="tab2">Table 2</xref>). In four patients, UBOs were present mainly in the cerebellum and the basal ganglia (patients 1, 2, 4 and 8). NF1 complications motivated frequent medical appointments and hospitalisations, an additional burden for patients and their families. For all the other patients (<xref ref-type="table" rid="tab2">Table 2</xref>) only mild NF1 features, such as café-au-laits spots, intertriginous freckling, few neurofibromas and/or Lisch nodules, were present. These patients all had subnormal IQ.</p>
</sec>
<sec id="sec3.3">
<title>3.3. NF1 and Learning Disabilities</title>
<p>All patients had learning disabilities that appeared as a primary or secondary cause of referral. For the patients who had subnormal IQ scores (<xref ref-type="table" rid="tab2">Table 2</xref>), it was common to find discrepancies in IQ sub-scales. Within each subscale, scores could vary widely (data not shown). Even if the patients received an<italic> average/mean</italic> IQ, their global intellectual efficiency was weaker when compared to the general population.</p>
<p>Specific learning disabilities were also common. They included specific language developmental delays (patients 5, 6, 9, 11; <xref ref-type="table" rid="tab2">Table 2</xref>), graphomotor delays (patients 5, 6, 7, 8; <xref ref-type="table" rid="tab2">Table 2</xref>) and developmental coordination disorders (dyspraxia) (patients 8, 9; <xref ref-type="table" rid="tab2">Table 2</xref>). Some patients also had comorbid ADHD (patients 5, 6, 8; <xref ref-type="table" rid="tab2">Table 2</xref>). The extensive developmental evaluation was crucial to disentangle diagnosis and also to guide further therapeutic propositions. Such specific propositions included school adaptations (such as having more time to finish evaluations, the use of computer to write), speech and reading therapies once or twice per week, and motor skills remediation once per week, that lead to improvement (nonpharmacological treatment; <xref ref-type="table" rid="tab2">Table 2</xref>).</p>
<p>Patients with intellectual disabilities (<xref ref-type="table" rid="tab1">Table 1</xref>) arguably presented learning difficulties. Standard tests for cognitive evaluation (such as the Wechsler intelligence scale for children, WISC [<xref ref-type="bibr" rid="B29">29</xref>]) were difficult to perform in such patients. In these cases, clinical evaluation and developmental scales were helpful (Brunet Lezine [<xref ref-type="bibr" rid="B18">18</xref>]), Terman Merrill [<xref ref-type="bibr" rid="B25">25</xref>]), as well as some psychosocial scales (Psychoeducational Profile (PEP) [<xref ref-type="bibr" rid="B23">23</xref>], Vineland [<xref ref-type="bibr" rid="B28">28</xref>]) that estimate performance in more ecologic day to day activities. In this context, specific evaluations of language, motor, and attentional domains are equally important to guide tailored intervention strategies. Intervention strategies were generally more global in the context of schooling for disabled children.</p>
</sec>
<sec id="sec3.4">
<title>3.4. NF1 and Attentional Issues</title>
<p>Four of our patients had an ADHD diagnosis, obtained after clinical assessment and a specific neuropsychological evaluation (Test of Everyday Attention for Children, TEA-Ch [<xref ref-type="bibr" rid="B24">24</xref>]). A fifth patient (patient 4; <xref ref-type="table" rid="tab1">Table 1</xref>) diagnosed with ADHD was evaluated through clinical observation and functional scales (Conners [<xref ref-type="bibr" rid="B20">20</xref>]), because the neuropsychological evaluation was difficult to perform given the intellectual deficit. In all cases, an ADHD diagnosis was made along with other comorbidities and was never isolated. Four patients were treated with methylphenidate and one was given specific cognitive training addressing attention. Three patients receiving methylphenidate improved and one stopped the treatment due to side effects.</p>
</sec>
<sec id="sec3.5">
<title>3.5. NF1, Emotional Problems and Emergent Psychopathology</title>
<p>The most frequent diagnosis was anxiety disorder and/or NF1 related stress (patients 1, 4, 7, 10, 11). Two visited for the evaluation and treatment of mood disturbances (patients 8, 11; <xref ref-type="table" rid="tab2">Table 2</xref>). Finally, another patient visited for psychiatric evaluation in the context of sexual assault (patient 3; <xref ref-type="table" rid="tab1">Table 1</xref>). Medication along with nonpharmacological treatments such as different types of psychotherapy were proposed and appeared to be helpful.</p>
</sec>
<sec id="sec3.6">
<title>3.6. NF1 and Autistic Spectrum Symptomatology</title>
<p>Four patients presented clear autistic features after clinically comprehensive/developmental assessment and additional assessment tools (patients 1, 2, 4; <xref ref-type="table" rid="tab1">Table 1</xref> and patient 9, <xref ref-type="table" rid="tab2">Table 2</xref>). Three patients with autistic features had concurrent intellectual disability (<xref ref-type="table" rid="tab1">Table 1</xref>). A fifth patient with an ongoing history of social difficulties had a pragmatic communication disorder (patient 5; <xref ref-type="table" rid="tab2">Table 2</xref>). Complementary psychological tests were helpful for the diagnosis (CARS [<xref ref-type="bibr" rid="B19">19</xref>], ADI [<xref ref-type="bibr" rid="B15">15</xref>], ADOS [<xref ref-type="bibr" rid="B16">16</xref>]). Treatment strategies addressed co-morbidities as well as core features of autism (e.g., social strategies in group) in outpatient settings or in the context of specific schooling models.</p>
</sec>
</sec>
<sec id="sec4">
<title>4. Discussion</title>
<p>This case series reflects the variety of problems and the complexity of severe NF1 paediatric patients. The gender bias reflected in our sample may result from the overrepresentation of boys in child and adolescent psychiatry consultations and therefore will not necessarily reflect the epidemiology of NF1 [<xref ref-type="bibr" rid="B30">30</xref>]. Also, the morbimortality of the disease, is mild to moderate in most cases. Nonetheless, clinical complications of NF1 can present a serious burden. This was the case for most of the patients reported here, who were referred to a special psychiatric clinic for rare diseases. The large heterogeneous phenotypic expression of NF1 is likely to be a consequence of the stochastics chain of events associated with NF1. At a molecular level, the reduced intracellular levels of neurofibromin found in NF1 patients induce impairments in learning and memory through imprecise, i.e. abnormally high or low RAS modulation and consequential gamma-aminobutyric acid (GABA)-mediated excessive inhibition in the hippocampus [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Also, patients with NF1 may show subcortical unidentified bright objects (UBOs) as we found in four of our patients. In all but one, UBOs were present in patients with intellectual disability and a multitude of somatic complications of the disease. UBOs are present in approximately 60–70% [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>] of the children with NF1 but tend to disappear with age. Histopathologic studies have shown that UBOs correspond to areas of myelin vacuolization with increased water content [<xref ref-type="bibr" rid="B34">34</xref>] and therefore, could reflect disordered myelination [<xref ref-type="bibr" rid="B35">35</xref>]. The presence of UBOs has been associated with lower intellectual ability [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>] and also visuospatial impairments when UBOs were located in the cerebellum [<xref ref-type="bibr" rid="B38">38</xref>]. The latter seems to be the case for patients 1 and 2 (<xref ref-type="table" rid="tab1">Table 1</xref>) and patient 8 (<xref ref-type="table" rid="tab2">Table 2</xref>) in our case series.</p>
<sec id="sec4.1">
<title>4.1. NF1 Cognitive Impairment and Learning Disabilities</title>
<p>In this case series, the patients presented either a degree of intellectual disability (<xref ref-type="table" rid="tab1">Table 1</xref>) or an average but heterogeneous cognitive profile with significant functional impairments (<xref ref-type="table" rid="tab2">Table 2</xref>). Many studies have now made clear how intelligence is only mildly affected in the vast majority of NF1 patients. However, specific impairments in cognition are very common (up to 80% of children in NF1 clinics [<xref ref-type="bibr" rid="B8">8</xref>]) and have a negative impact in the quality of life. Some specific deficits have been reported to NF1: visual-spatial deficits [<xref ref-type="bibr" rid="B39">39</xref>], speech and language deficits, motor skill deficits [<xref ref-type="bibr" rid="B40">40</xref>], social skill deficits [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B41">41</xref>] and attentional deficits [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B42">42</xref>]. All may lead to learning disabilities and further emotional suffering. The presence of visual-spatial and attentional deficits has been robustly replicated [<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B43">43</xref>]. However, research has revealed contradictory results regarding motor skills and language performance in patients with NF1 [<xref ref-type="bibr" rid="B7">7</xref>]. Moderate to severe intellectual disability and severe clinical cases seemed to be the focus of interest of early works in neurofibromatosis [<xref ref-type="bibr" rid="B44">44</xref>] but severe cases of NF1 have received little attention recently.</p>
</sec>
<sec id="sec4.2">
<title>4.2. NF1 and ADHD</title>
<p>In all our NF1-ADHD patients, the ADHD diagnosis was made along with other comorbidities and was never isolated. Patients with NF1 present more symptoms and are more often diagnosed with ADHD than the general population. Prevalence estimates range from 30% to 50% [<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>], which are higher than those expected in the general population, i.e. about 5% in children and 2.5% in adults [<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>].</p>
<p>Clinical and cognitive profiles of both ADHD patients with and without NF1 are heterogeneous. Individuals are affected in different domains of attention, impulsivity, hyperactivity and executive functioning, and to different degrees [<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B49">49</xref>]. Visual attention seems consistently impaired in NF1 patients [<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B51">51</xref>] and would lead to instability in focusing attention and lower resistance to interference in controlled tasks but also to inattentive and impulsive behaviour in natural environments.</p>
<p>Importantly, ADHD-NF1 patients seem responsive to methylphenidate [<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B46">46</xref>]. This improvement has been also reported for children with IQs lower than 80 [<xref ref-type="bibr" rid="B46">46</xref>]. In our case series, four of the patients diagnosed with ADHD were treated with methylphenidate, three showing a great improvement and one dropping out of treatment due to side effects.</p>
<p>The high frequency of ADHD in children with NF1, as well as the demonstrated significant comorbidity of ADHD with literacy learning disabilities [<xref ref-type="bibr" rid="B8">8</xref>] and social skills problems [<xref ref-type="bibr" rid="B52">52</xref>] indicates the need for thorough screening of ADHD symptomatology in all children with NF1 [<xref ref-type="bibr" rid="B45">45</xref>]. Besides, the impact of attention deficits and behaviour problems in children with NF1 often leads to lower social acceptance and lack of self-confidence/esteem. When emotional problems are secondary to ADHD, effective treatment of ADHD can improve them both [<xref ref-type="bibr" rid="B46">46</xref>].</p>
</sec>
<sec id="sec4.3">
<title>4.3. NF1 and Autistic Spectrum Symptomatology</title>
<p>After some early work evoking associations between autism and NF1 [<xref ref-type="bibr" rid="B53">53</xref>] there is a re-enacted concern regarding ASD and NF1. Since Huijbregts and de Sonneville [<xref ref-type="bibr" rid="B54">54</xref>] showed that NF1 impairments in cognitive control (i.e. a combination of processing speed, working memory, inhibitory control, and emotional processing functions) is associated with the presence of autistic traits, several studies have explored the prevalence of ASD symptoms in NF1 populations.</p>
<p>Studies focusing on social impairments as a continuous variable within the social responsiveness scale (SRS) [<xref ref-type="bibr" rid="B55">55</xref>–<xref ref-type="bibr" rid="B58">58</xref>] showed that NF1 patients present more social impairments than the general population (up to 40% in some samples [<xref ref-type="bibr" rid="B56">56</xref>]). Whether or not this is enough to state that ASD is increased in NF1 patients is another question. First, ASD screening tools are not meant to provide a diagnosis of ASD, but rather identify children who should be further evaluated. Second, NF1 patients with high SRS scores show mild to moderate ASD symptomatology (e.g. latter diagnosis during school years; no stereotyped behaviours) [<xref ref-type="bibr" rid="B57">57</xref>]. We believe that research should explore further the meaning of ASD symptomatology in NF1. Given the rarity of stereotyped behaviours in NF1, perhaps the DSM-5 diagnosis of social communication disorder will be more appropriate in some cases? Also, is it legitimate to use SRS score as a continuous variable? Indeed, when re-analysing the largest cohort of NF1 so far that reported SRS scores [<xref ref-type="bibr" rid="B59">59</xref>] we found that the best model to predict data distribution using admixture analysis was a bimodal distribution (<xref ref-type="fig" rid="fig1">Figure 1</xref>), with a large group of patients with a mean SRS score equal to 55 (red curve), and a smaller group of patients with a higher mean SRS score equal to 70 (green curve). This means that considering SRS as a continuous variable showing a normal distribution may be inappropriate. This also means that NF1 phenotype heterogeneity might be better understood separating subgroups of patients as it has been shown in other genetically complex neurodevelopmental disorders.</p>
<p>However, we do believe that rare typical cases of ASD can also be encountered in NF1. Three patients in this case series presented an unequivocal profile of ASD comorbid with intellectual disability. Several authors postulated that autism associated with neurogenetic syndromes can be classified as “complex autism” or “syndromic autism” [<xref ref-type="bibr" rid="B60">60</xref>–<xref ref-type="bibr" rid="B62">62</xref>]. Complex autism is characterised by lower IQ, higher rates of comorbidities both psychiatric and somatic, and higher rates of epilepsy [<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>]. For these severe cases, this classification may be useful to better explore their clinical profile and tailor treatment to the child's needs [<xref ref-type="bibr" rid="B65">65</xref>].</p>
</sec>
<sec id="sec4.4">
<title>4.4. NF1 and Emotional Problems</title>
<p>NF1 has also significant social and psychological consequences on individuals and their families [<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Most patients of this case series were referred with emotional problems. While some (<italic>n</italic> = 7) had behavioural difficulties (sometimes secondary to ADHD or to learning disabilities), others expressed internalising symptoms such as anxiety or depression. These conditions can often be found in NF1 [<xref ref-type="bibr" rid="B67">67</xref>]. The emotional impact of cosmetic deformities, the fear of malignancy, and the medical complications, such as the management of hypertension or the need for surgical interventions should be carefully evaluated and not be neglected. Learning difficulties can also generate feelings of low self-esteem and inefficiency that can last in time. In addition, the impact of attention deficits and behaviour problems in children with NF1 often leads to lower social acceptance and lack of self-confidence. As mentioned previously, when emotional problems are secondary to ADHD, effective treatment of ADHD can improve them both [<xref ref-type="bibr" rid="B46">46</xref>]. Besides, parents of NF1 children experience greater stress than other parents [<xref ref-type="bibr" rid="B68">68</xref>], sometimes associated with feelings of guilt regarding the genetic transmission of NF1. The parents should also receive proper care.</p>
</sec>
<sec id="sec4.5">
<title>4.5. Treatment Modalities and Outcome</title>
<p>Strategies that decrease either RAS activity or GABA-mediated inhibition have been suggested to specifically treat learning and emotional deficits associated with NF1. Pharmacologically targeting this pathway with an HMG-CoA reductase inhibitor (an anti-RAS agent), such as lovastatin [<xref ref-type="bibr" rid="B69">69</xref>] evidenced some encouraging results in animal models. However, to date, clinical trials with NF1 patients have shown modest results [<xref ref-type="bibr" rid="B70">70</xref>–<xref ref-type="bibr" rid="B72">72</xref>]. Therefore, current treatment options remain symptomatic. The heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with NF1. The outcome is therefore variable, different for each patient.</p>
</sec>
</sec>
<sec id="sec5">
<title>5. Conclusions</title>
<p>In severe cases of NF1 with important psychiatric morbidity, it can sometimes be difficult to disentangle specific domains of impairment, as cognition as a whole is complex. In day-to-day activities, more than one cognitive domain is needed to perform adequately, making the task of disentanglement even more challenging. This is why a multidimensional and longitudinal clinical evaluation is warranted when assessing patients.</p>
<p>Phenotype-genotype correlations tend to subscribe the idea that behavioural manifestations present themselves with continuous variation. This type of pattern was proposed for NF1 autistic symptoms [<xref ref-type="bibr" rid="B59">59</xref>]. However, we believe that more complex phenotype/genotype association occurs in NF1 for psychiatric comorbidity including ASD symptomatology. Similarly to other genetic conditions such as juvenile myotonic dystrophy [<xref ref-type="bibr" rid="B73">73</xref>], or tuberous sclerosis [<xref ref-type="bibr" rid="B74">74</xref>], bimodal phenotypic patterns of intelligence/cognitive performance seem to adapt better to the distribution of IQ scores in these populations. In terms of clinical implications, the heterogeneity of NF1 phenotypical manifestations needs to be considered when developing assessment and remediation approaches for children with NF1.</p>
</sec>
</body>
<back>
<sec sec-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare that they have no conflicts of interest.</p>
</sec>
<sec>
<title>Acknowledgements</title>
<p>The authors wish to thank Joana Queiroz for the English language-editing.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Friedman</surname>
<given-names>J. M.</given-names>
</name>
</person-group>
<article-title>Epidemiology of neurofibromatosis type</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics</italic>
<year>1999</year>
<volume>89</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19990326)89:1&lt;1::AID-AJMG3&gt;3.0.CO;2-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-0033605484</pub-id>
<pub-id pub-id-type="pmid">10469430</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stumpf</surname>
<given-names>D. A.</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis. conference statement, national institutes of health consensus development conference</article-title>
<source/>
<italic toggle="yes">Archives of Neurology</italic>
<year>1988</year>
<volume>45</volume>
<issue>5</issue>
<fpage>575</fpage>
<lpage>578</lpage>
<pub-id pub-id-type="pmid">3128965</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyd</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Korf</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Theos</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Journal of the American Academy of Dermatology</italic>
<year>2009</year>
<volume>61</volume>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1016/j.jaad.2008.12.051</pub-id>
<pub-id pub-id-type="other">2-s2.0-66949142979</pub-id>
<pub-id pub-id-type="pmid">19539839</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Costa</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Federov</surname>
<given-names>N. B.</given-names>
</name>
<name>
<surname>Kogan</surname>
<given-names>J. H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Nature</italic>
<year>2002</year>
<volume>415</volume>
<issue>6871</issue>
<fpage>526</fpage>
<lpage>530</lpage>
<pub-id pub-id-type="pmid">11793011</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plotkin</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Albers</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Babovic-Vuksanovic</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Update from the 2013 international neurofibromatosis conference</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics. Part A</italic>
<year>2014</year>
<volume>164</volume>
<issue>12</issue>
<fpage>2969</fpage>
<lpage>2978</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36754</pub-id>
<pub-id pub-id-type="other">2-s2.0-84911191642</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isenberg</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Templer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Titus</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D. H.</given-names>
</name>
</person-group>
<article-title>Attention skills in children with neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Journal of Child Neurology</italic>
<year>2013</year>
<volume>28</volume>
<issue>1</issue>
<fpage>45</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1177/0883073812439435</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867245213</pub-id>
<pub-id pub-id-type="pmid">22496119</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lehtonen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Howie</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Trump</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>S. M.</given-names>
</name>
</person-group>
<article-title>Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2012</year>
<volume>55</volume>
<issue>2</issue>
<fpage>111</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04399.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872595392</pub-id>
<pub-id pub-id-type="pmid">22934576</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Shores</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K. N.</given-names>
</name>
</person-group>
<article-title>The nature and frequency of cognitive deficits in children with neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2005</year>
<volume>65</volume>
<issue>7</issue>
<fpage>1037</fpage>
<lpage>1044</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000179303.72345.ce</pub-id>
<pub-id pub-id-type="other">2-s2.0-26444599545</pub-id>
<pub-id pub-id-type="pmid">16217056</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferner</surname>
<given-names>R. E.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Weinman</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Intellectual impairment in neurofibromatosis 1</article-title>
<source/>
<italic toggle="yes">Journal of the Neurological Sciences</italic>
<year>1996</year>
<volume>138</volume>
<issue>1-2</issue>
<fpage>125</fpage>
<lpage>133</lpage>
<pub-id pub-id-type="doi">10.1016/0022-510X(96)00022-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-0029882903</pub-id>
<pub-id pub-id-type="pmid">8791250</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douniol</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jacquette</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric and cognitive phenotype of childhood myotonic dystrophy type 1 includes internalising disorder, borderline intelligence, visual spatial construction disability and attention deficit disorder</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2012</year>
<volume>54</volume>
<issue>10</issue>
<fpage>905</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04379.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84866351248</pub-id>
<pub-id pub-id-type="pmid">22861906</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonnot</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thuilleaux</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Consoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cabal-Berthoumieu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tauber</surname>
<given-names>M. T.</given-names>
</name>
</person-group>
<article-title>Psychotropic treatments in Prader Willi syndrome: a critical review of published literature</article-title>
<source/>
<italic toggle="yes">European Journal of Pediatrics</italic>
<year>2016</year>
<volume>175</volume>
<issue>1</issue>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1007/s00431-015-2670-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84954395404</pub-id>
<pub-id pub-id-type="pmid">26584571</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Consoli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Raffin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Medical and developmental risk factors of catatonia in children and adolescents: a 17-year prospective study</article-title>
<source/>
<italic toggle="yes">Schizophrenia Research</italic>
<year>2012</year>
<volume>137</volume>
<fpage>151</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1016/j.schres.2012.02.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-84860836040</pub-id>
<pub-id pub-id-type="pmid">22401837</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coutinho</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Câmara-Costa</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kemlin</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bilette de Villemeur</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dellatolas</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The discrepancy between performance-based measures and questionnaires when assessing clinical outcomes and quality of life in pediatric patients with neurological disorders</article-title>
<source/>
<italic toggle="yes">Applied Neuropsychology: Child</italic>
<year>2017</year>
<volume>6</volume>
<issue>4</issue>
<fpage>255</fpage>
<lpage>261</lpage>
<pub-id pub-id-type="doi">10.1080/21622965.2016.1146141</pub-id>
<pub-id pub-id-type="other">2-s2.0-84969271191</pub-id>
<pub-id pub-id-type="pmid">27182681</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spurlock</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bennett</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Chuzhanova</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype</article-title>
<source/>
<italic toggle="yes">Journal of Medical Genetics</italic>
<year>2009</year>
<volume>46</volume>
<issue>7</issue>
<fpage>431</fpage>
<lpage>437</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.2008.065474</pub-id>
<pub-id pub-id-type="other">2-s2.0-67650489624</pub-id>
<pub-id pub-id-type="pmid">19443465</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Le Couteur</surname>
</name>
<name>
<surname> Lord</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Autism Diagnostic Interview-Revised (ADI-R). Autism Genetic Resource Exchange</italic>
<year> 2003</year>
<publisher-loc>Los Angeles, CA</publisher-loc>
<publisher-name>ADI-R</publisher-name>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lord</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Rutter</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Goode</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism diagnostic observation schedule: a standardized observation of communicative and social behavior</article-title>
<source/>
<italic toggle="yes">Journal of Autism and Developmental Disorders</italic>
<year>1989</year>
<volume>19</volume>
<issue>2</issue>
<fpage>185</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1007/BF02211841</pub-id>
<pub-id pub-id-type="other">2-s2.0-0024369122</pub-id>
<pub-id pub-id-type="pmid">2745388</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Hamstra-Bletz</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Bie</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Brinker</surname>
<given-names>B. D.</given-names>
</name>
</person-group>
<article-title>BHK—concise evaluation scale for children handwriting</article-title>
<source/>
<italic toggle="yes">Beknopte Beoordelingsmethode Voor Kinderhandschriften (Une Méthode Rapide dévaluation De L’écriture Chez L’enfant</italic>
<year>1987</year>
<publisher-loc>Lisse</publisher-loc>
<publisher-name>Swets &amp; Zeitlinger</publisher-name>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Brunet</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Lézine</surname>
<given-names>I. </given-names>
</name>
<name>
<surname>Josse</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Le développement psychologique de la première enfance 1951. Nouvelle version révisée</article-title>
<source/>
<italic toggle="yes">Echelle de Développement Psychomoteur De La Première Enfance, E.A.P</italic>
<year>1997</year>
<publisher-loc>Paris</publisher-loc>
<publisher-name>PUF</publisher-name>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Schopler</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Reichler</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Renner</surname>
<given-names>B. R.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">The Childhood Autism Rating Scale1937</italic>
<year>1988</year>
<publisher-loc>Los Angeles</publisher-loc>
<publisher-name>Western Psychological Services</publisher-name>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Conners</surname>
<given-names>C. K.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Conners’ Continuous Performance Test Version 5</italic>
<year>2004</year>
<edition>2</edition>
<publisher-loc>Toronto</publisher-loc>
<publisher-name>Pearson Canada Assessment</publisher-name>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="other">
<person-group person-group-type="author">
<name>
<surname>Thibault</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Lenfant</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Helloin</surname>
<given-names>M. C.</given-names>
</name>
</person-group>
<article-title>Bilan informatisé pour l’examen du langage et des compétences transversales chez l’enfant de 8 à 11 ans (ou scolarisé du CE2 au CM2)</article-title>
<year>2003</year>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Korkman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kirk</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kemp</surname>
<given-names>S.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">NEPSY-II: Bilan Neuropsychologique De L’enfant [Neuropsychological Test for Children]. Bilan Neuropsychologique de l’Enfant (NEPSY)</italic>
<year>2012</year>
<edition>2</edition>
<publisher-loc>Paris</publisher-loc>
<publisher-name>Edition du Centre de Psychologie Appliqué</publisher-name>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Schopler</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Reichler</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Bashford</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lansing</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>L. M.</given-names>
</name>
</person-group>
<article-title>Individual Assessment and Treatment for Autistic and Developmentally Disabled Children: Vol. 1.</article-title>
<source/>
<italic toggle="yes">Psychoeducational Profile Revised PEP</italic>
<year>1990</year>
<edition>3</edition>
<publisher-loc>USA, Austin</publisher-loc>
<publisher-name>Pro-Ed</publisher-name>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manly</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nimmo-Smith</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>I. H.</given-names>
</name>
</person-group>
<article-title>The differential assessment of children’s attention: the test of everyday attention for children (TEA-Ch), normative sample and ADHD performance</article-title>
<source/>
<italic toggle="yes">Journal of Child Psychology and Psychiatry</italic>
<year>2001</year>
<volume>42</volume>
<issue>8</issue>
<fpage>1065</fpage>
<lpage>1081</lpage>
<pub-id pub-id-type="doi">10.1017/S0021963001007909</pub-id>
<pub-id pub-id-type="pmid">11806689</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Terman</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Merrill</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Samuel</surname>
<given-names>R.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Stanford–Binet Intelligence Scale: Manual for the Third Revision Form L-M with Revised IQ Tables</italic>
<year>1960</year>
<publisher-loc>Pinneau. Boston (MA)</publisher-loc>
<publisher-name>Houghton Mifflin</publisher-name>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wallon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mesmin</surname>
<given-names>C.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">Test, de la figure complexe de Rey (Rey–Osterrieth complex figure): A. Rey Test de la figure complexe de Rey</italic>
<year>2009</year>
<publisher-loc>Paris</publisher-loc>
<publisher-name>Edition du Centre de Psychologie Appliqué</publisher-name>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pons</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>de Rosnay</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Emotional comprehension between 3 and 11 years: developmental periods and hierarchical organization</article-title>
<source/>
<italic toggle="yes">European Journal of Developmental Psychology</italic>
<year>2004</year>
<volume>1</volume>
<issue>2</issue>
<fpage>127</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1080/17405620344000022</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sparrow</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Balla</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Cicchetti</surname>
<given-names>D. V.</given-names>
</name>
<name>
<surname>Balboni</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pedrabissi</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Vineland Adaptive Behaviour Scales</article-title>
<source/>
<italic toggle="yes">Circle Pines, MN: American Guidance Service</italic>
<year>2003</year>
<publisher-loc>Florence</publisher-loc>
<publisher-name>O.S.</publisher-name>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Wechsler</surname>
<given-names>D.</given-names>
</name>
</person-group>
<source/>
<italic toggle="yes">The Wechsler Intelligence Scale for Children—Fourth Edition</italic>
<year>2003</year>
<publisher-loc>London</publisher-loc>
<publisher-name>Pearson</publisher-name>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinhause</surname>
<given-names>H. C.</given-names>
</name>
</person-group>
<article-title>Child and adolescent psychiatric disorders in a public service over seventy years</article-title>
<source/>
<italic toggle="yes">European Child and Adolescent Psychiatry</italic>
<year>1997</year>
<volume>6</volume>
<issue>1</issue>
<fpage>42</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1007/BF00573639</pub-id>
<pub-id pub-id-type="other">2-s2.0-0030936356</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Mangoura</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons</article-title>
<source/>
<italic toggle="yes">Developmental Brain Research</italic>
<year>2001</year>
<volume>130</volume>
<issue>2</issue>
<fpage>231</fpage>
<lpage>248</lpage>
<pub-id pub-id-type="doi">10.1016/S0165-3806(01)00190-0</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035944533</pub-id>
<pub-id pub-id-type="pmid">11675125</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyman</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Gill</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Shores</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>T2-Hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning</article-title>
<source/>
<italic toggle="yes">Journal of Neurology, Neurosurgery and Psychiatry</italic>
<year>2007</year>
<volume>78</volume>
<fpage>1088</fpage>
<lpage>1091</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.2006.108134</pub-id>
<pub-id pub-id-type="other">2-s2.0-34848884867</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopes Ferraz Filho</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Munis</surname>
<given-names>M. P.</given-names>
</name>
<name>
<surname>Soares Souza</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sanches</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Goloni-Bertollo</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Pavarino-Bertelli</surname>
<given-names>E. C.</given-names>
</name>
</person-group>
<article-title>Unidentified bright objects on brain MRI in children as a diagnostic criterion for neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Pediatric Radiology</italic>
<year>2008</year>
<volume>38</volume>
<issue>3</issue>
<fpage>305</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1007/s00247-007-0712-x</pub-id>
<pub-id pub-id-type="other">2-s2.0-39049168113</pub-id>
<pub-id pub-id-type="pmid">18231788</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>DiPaolo</surname>
<given-names>D. P.</given-names>
</name>
<name>
<surname>Zimmerman</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Rorke</surname>
<given-names>L. B.</given-names>
</name>
<name>
<surname>Zackai</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Bilaniuk</surname>
<given-names>L. T.</given-names>
</name>
<name>
<surname>Yachnis</surname>
<given-names>A. T.</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain</article-title>
<source/>
<italic toggle="yes">Radiology</italic>
<year>1995</year>
<volume>195</volume>
<issue>3</issue>
<fpage>721</fpage>
<lpage>724</lpage>
<pub-id pub-id-type="doi">10.1148/radiology.195.3.7754001</pub-id>
<pub-id pub-id-type="other">2-s2.0-0029053230</pub-id>
<pub-id pub-id-type="pmid">7754001</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sevick</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Barkovich</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Berg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lempert</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Evolution of white matter lesions in neurofibromatosis type 1: MR findings</article-title>
<source/>
<italic toggle="yes">AJR. American Journal Roentgenology</italic>
<year>1992</year>
<volume>159</volume>
<issue>1</issue>
<fpage>171</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.2214/ajr.159.1.1609692</pub-id>
<pub-id pub-id-type="other">2-s2.0-0026716566</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joy</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>de Silva</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Neuropsychological function and MRI abnormalities in neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>1995</year>
<volume>37</volume>
<issue>10</issue>
<fpage>906</fpage>
<lpage>914</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.1995.tb11943.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0028847343</pub-id>
<pub-id pub-id-type="pmid">7493724</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Payne</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Pickering</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Porter</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics. Part A</italic>
<year>2014</year>
<volume>164</volume>
<issue>3</issue>
<fpage>661</fpage>
<lpage>665</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36338</pub-id>
<pub-id pub-id-type="other">2-s2.0-84894254334</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piscitelli</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Digilio</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Capolino</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Longo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Di Ciommo</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2012</year>
<volume>54</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2011.04139.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-83855163457</pub-id>
<pub-id pub-id-type="pmid">22107256</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics</italic>
<year>2000</year>
<volume>97</volume>
<issue>2</issue>
<fpage>119</fpage>
<lpage>127</lpage>
<pub-id pub-id-type="doi">10.1002/1096-8628(200022)97:2&lt;119::AID-AJMG3&gt;3.0.CO;2-3</pub-id>
<pub-id pub-id-type="pmid">11180219</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rietman</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Oostenbrink</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bongers</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Motor problems in children with neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Journal of Neurodevelopmental Disorders</italic>
<year>2017</year>
<volume>19</volume>
<issue>9</issue>
<fpage>p. 19</fpage>
<pub-id pub-id-type="doi">10.1186/s11689-017-9198-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019565121</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pierpont</surname>
<given-names>E. I.</given-names>
</name>
<name>
<surname>Hudock</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Foy</surname>
<given-names>A. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Social skills in children with RASopathies: a comparison of Noonan syndrome and neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Journal of Neurodevelopmental Disorders</italic>
<year>2018</year>
<volume>10</volume>
<issue>1</issue>
<fpage>p. 21</fpage>
<pub-id pub-id-type="doi">10.1186/s11689-018-9239-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-85048719198</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lion-François</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gueyffier</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mercier</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial</article-title>
<source/>
<italic toggle="yes">Orphanet Journal of Rare Disorders</italic>
<year>2014</year>
<volume>9</volume>
<issue>1</issue>
<fpage>p. 142</fpage>
<pub-id pub-id-type="doi">10.1186/s13023-014-0142-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-84991277915</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lidzba</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Granström</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lindenau</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mautner</surname>
<given-names>V. F.</given-names>
</name>
</person-group>
<article-title>The adverse influence of attention-deficit disorder with or without hyperactivity on cognition in neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2012</year>
<volume>54</volume>
<issue>10</issue>
<fpage>892</fpage>
<lpage>897</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04377.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84866402145</pub-id>
<pub-id pub-id-type="pmid">22881119</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinsard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rufo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Mental retardation and Recklinghausen’s neurofibromatosis</article-title>
<source/>
<italic toggle="yes">Journal de Genetique Humaine</italic>
<year>1975</year>
<volume>23</volume>
<fpage>228</fpage>
<lpage>229</lpage>
<pub-id pub-id-type="pmid">814202</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Payne</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hyman</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shores</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Assessment of executive function and attention in children with neurofibromatosis type 1: relationships between cognitive measures and real-world behaviour</article-title>
<source/>
<italic toggle="yes">Child Neuropsychology</italic>
<year>2011</year>
<volume>17</volume>
<issue>4</issue>
<fpage>313</fpage>
<lpage>329</lpage>
<pub-id pub-id-type="doi">10.1080/09297049.2010.542746</pub-id>
<pub-id pub-id-type="other">2-s2.0-79960461456</pub-id>
<pub-id pub-id-type="pmid">21347908</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mautner</surname>
<given-names>V. F.</given-names>
</name>
<name>
<surname>Kluwe</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Thakker</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Leark</surname>
<given-names>R. A.</given-names>
</name>
</person-group>
<article-title>Treatment of ADHD in neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2002</year>
<volume>44</volume>
<issue>3</issue>
<fpage>164</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2002.tb00780.x</pub-id>
<pub-id pub-id-type="pmid">12005317</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polanczyk</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>de Lima</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Horta</surname>
<given-names>B. L.</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Rohde</surname>
<given-names>L. A.</given-names>
</name>
</person-group>
<article-title>The worldwide prevalence of ADHD: a systematic review and metaregression analysis</article-title>
<source/>
<italic toggle="yes">American Journal of Psychiatry</italic>
<year>2007</year>
<volume>164</volume>
<issue>6</issue>
<fpage>942</fpage>
<lpage>948</lpage>
<pub-id pub-id-type="doi">10.1176/ajp.2007.164.6.942</pub-id>
<pub-id pub-id-type="other">2-s2.0-34250832736</pub-id>
<pub-id pub-id-type="pmid">17541055</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Czobor</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bálint</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mészáros</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bitter</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis</article-title>
<source/>
<italic toggle="yes">British Journal of Psychiatry</italic>
<year>2009</year>
<volume>194</volume>
<issue>3</issue>
<fpage>204</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.107.048827</pub-id>
<pub-id pub-id-type="other">2-s2.0-62149113614</pub-id>
<pub-id pub-id-type="pmid">19252145</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seidman</surname>
<given-names>L. J.</given-names>
</name>
</person-group>
<article-title>Neuropsychological functioning in people with ADHD across the lifespan</article-title>
<source/>
<italic toggle="yes">Clinical Psychology Review</italic>
<year>2006</year>
<volume>26</volume>
<issue>4</issue>
<fpage>466</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="doi">10.1016/j.cpr.2006.01.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-33745714234</pub-id>
<pub-id pub-id-type="pmid">16473440</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michael</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Garcia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herbillon</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lion-François</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Reactivity to visual signals in neurofibromatosis type 1: is everything ok?</article-title>
<source/>
<italic toggle="yes">Neuropsychology</italic>
<year>2014</year>
<volume>28</volume>
<issue>3</issue>
<fpage>423</fpage>
<lpage>428</lpage>
<pub-id pub-id-type="doi">10.1037/neu0000046</pub-id>
<pub-id pub-id-type="other">2-s2.0-84921958164</pub-id>
<pub-id pub-id-type="pmid">24274026</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ribeiro</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>D’Almeida</surname>
<given-names>O. C.</given-names>
</name>
<name>
<surname>Ramos</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Saraiva</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>E. D.</given-names>
</name>
<name>
<surname>Castelo-Branco</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Abnormal late visual responses and alpha oscillations in neurofibromatosis type 1: a link to visual and attention deficits</article-title>
<source/>
<italic toggle="yes">Journal of Neurodevelopmental Disorders</italic>
<year>2014</year>
<volume>6</volume>
<issue>1</issue>
<fpage>p. 4</fpage>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barton</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>North</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Social skills of children with neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2004</year>
<volume>46</volume>
<issue>8</issue>
<fpage>553</fpage>
<lpage>563</lpage>
<pub-id pub-id-type="doi">10.1111/j.1469-8749.2004.tb01014.x</pub-id>
<pub-id pub-id-type="pmid">15287247</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mbarek</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Marouillat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Martineau</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Barthélémy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Müh</surname>
<given-names>J.‐P.</given-names>
</name>
<name>
<surname>Andres</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Association study of the NF1 gene and autistic disorder</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics</italic>
<year>1999</year>
<volume>88</volume>
<issue>6</issue>
<fpage>729</fpage>
<lpage>732</lpage>
<pub-id pub-id-type="doi">10.1002/(SICI)1096-8628(19991215)88:6&lt;729::AID-AJMG26&gt;3.3.CO;2-H</pub-id>
<pub-id pub-id-type="pmid">10581497</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huijbregts</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>de Sonneville</surname>
<given-names>L. M.</given-names>
</name>
</person-group>
<article-title>Does cognitive impairment explain behavioral and social problems of children with neurofibromatosis type 1?</article-title>
<source/>
<italic toggle="yes">Behavior Genetics</italic>
<year>2011</year>
<volume>41</volume>
<issue>3</issue>
<fpage>430</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1007/s10519-010-9430-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-79958195841</pub-id>
<pub-id pub-id-type="pmid">21184163</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lehtonen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huson</surname>
<given-names>S. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2013</year>
<volume>55</volume>
<issue>2</issue>
<fpage>139</fpage>
<lpage>145</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12043</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872586906</pub-id>
<pub-id pub-id-type="pmid">23163236</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Vélez</surname>
<given-names>J. I.</given-names>
</name>
<name>
<surname>Kardel</surname>
<given-names>P. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2013</year>
<volume>55</volume>
<issue>2</issue>
<fpage>131</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12038</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872586282</pub-id>
<pub-id pub-id-type="pmid">23163951</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plasschaert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Descheemaeker</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Van Eylen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Noens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Steyaert</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Legius</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics Part B, Neuropsychiatric genetics</italic>
<year>2015</year>
<volume>168</volume>
<issue>1</issue>
<fpage>72</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.32280</pub-id>
<pub-id pub-id-type="other">2-s2.0-84919459048</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tinker</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Viskochil</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Mathiesen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>K. N.</given-names>
</name>
<name>
<surname>Stevenson</surname>
<given-names>D. A.</given-names>
</name>
</person-group>
<article-title>Screening children with neurofibromatosis type 1 for autism spectrum disorder</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics. Part A</italic>
<year>2014</year>
<volume>164</volume>
<fpage>1706</fpage>
<lpage>1712</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36549</pub-id>
<pub-id pub-id-type="other">2-s2.0-84902545180</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Acosta</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Garg</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Disease burden and symptom structure of autism in neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">JAMA Psychiatry</italic>
<year>2016</year>
<volume>73</volume>
<issue>12</issue>
<fpage>1276</fpage>
<lpage>1284</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.2600</pub-id>
<pub-id pub-id-type="other">2-s2.0-85011419253</pub-id>
<pub-id pub-id-type="pmid">27760236</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miles</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bagby</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Essential versus complex autism: Definition of fundamental prognostic subtypes</article-title>
<source/>
<italic toggle="yes">American Journal of Medical Genetics Part A</italic>
<year>2005</year>
<volume>135</volume>
<issue>2</issue>
<fpage>171</fpage>
<lpage>180</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.30590</pub-id>
<pub-id pub-id-type="other">2-s2.0-20044382649</pub-id>
<pub-id pub-id-type="pmid">15887228</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Eeghen</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Pulsifer</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Merker</surname>
<given-names>V. L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach</article-title>
<source/>
<italic toggle="yes">Developmental Medicine and Child Neurology</italic>
<year>2013</year>
<volume>55</volume>
<issue>2</issue>
<fpage>146</fpage>
<lpage>153</lpage>
<pub-id pub-id-type="doi">10.1111/dmcn.12044</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872535697</pub-id>
<pub-id pub-id-type="pmid">23205844</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pichard</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tordjman</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Specific genetic disorders and autism: clinical contribution towards their identification</article-title>
<source/>
<italic toggle="yes">Journal of Autism and Developmental Disorders</italic>
<year>2005</year>
<volume>35</volume>
<issue>1</issue>
<fpage>103</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1007/s10803-004-1038-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-21244472348</pub-id>
<pub-id pub-id-type="pmid">15796126</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amiet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gourfinkel-An</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bouzamondo</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in autism is associated with mental retardation and gender: evidence from a meta-analysis</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2008</year>
<volume>64</volume>
<issue>7</issue>
<fpage>577</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.04.030</pub-id>
<pub-id pub-id-type="other">2-s2.0-51049093585</pub-id>
<pub-id pub-id-type="pmid">18565495</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amiet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gourfinkel-An</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy in multiplex autism pedigrees is associated with intellectual disability and known genetic and nongenetic causes, but not with gender</article-title>
<source/>
<italic toggle="yes">Molecular Autism</italic>
<year>2013</year>
<volume>4</volume>
<issue>1</issue>
<fpage>p. 47</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-4-47</pub-id>
<pub-id pub-id-type="other">2-s2.0-84888350760</pub-id>
<pub-id pub-id-type="pmid">24289166</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xavier</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bursztejn</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Stiskin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Autism spectrum disorders: A developmental and dimensional approach toward a tailored therapeutic program</article-title>
<source/>
<italic toggle="yes">Research in Autism Spectrum Disorder</italic>
<year>2015</year>
<volume>18</volume>
<fpage>21</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1016/j.rasd.2015.06.011</pub-id>
<pub-id pub-id-type="other">2-s2.0-84938350305</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Benjamin</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Colley</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Donnai</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kingston</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kerzin-Storrar</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Neurofibromatosis type 1 (NF1) knowledge, experience and reproductive decisions of affected patients and families</article-title>
<source/>
<italic toggle="yes">Journal of Medical Genetics</italic>
<year>1993</year>
<volume>30</volume>
<issue>7</issue>
<fpage>567</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1136/jmg.30.7.567</pub-id>
<pub-id pub-id-type="pmid">8411029</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>North</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>G. H.</given-names>
</name>
<name>
<surname>MacCollin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Riccardi</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Cognitive function and academic performance</article-title>
<source/>
<italic toggle="yes">In Neurofibromatosis: Phenotype, Natural History and Pathogenesis</italic>
<year>1999</year>
<edition>3rd</edition>
<publisher-loc>Baltimore</publisher-loc>
<publisher-name>John Hopkins University Press</publisher-name>
<fpage>p. 380</fpage>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Esposito</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marotta</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Roccella</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Pediatric neurofibromatosis 1 and parental stress: a multicenter study</article-title>
<source/>
<italic toggle="yes">Neuropsychiatric Disease Treatment</italic>
<year>2014</year>
<volume>10</volume>
<fpage>141</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S55518</pub-id>
<pub-id pub-id-type="other">2-s2.0-84893492327</pub-id>
<pub-id pub-id-type="pmid">24489471</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kushner</surname>
<given-names>S. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1</article-title>
<source/>
<italic toggle="yes">Current Biology</italic>
<year>2005</year>
<volume>15</volume>
<issue>21</issue>
<fpage>1961</fpage>
<lpage>1967</lpage>
<pub-id pub-id-type="doi">10.1016/j.cub.2005.09.043</pub-id>
<pub-id pub-id-type="other">2-s2.0-27644517404</pub-id>
<pub-id pub-id-type="pmid">16271875</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bearden</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Hellemann</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Rosser</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I</article-title>
<source/>
<italic toggle="yes">Annals of Clinical and Translational Neurology</italic>
<year>2016</year>
<volume>3</volume>
<issue>4</issue>
<fpage>266</fpage>
<lpage>279</lpage>
<pub-id pub-id-type="doi">10.1002/acn3.288</pub-id>
<pub-id pub-id-type="other">2-s2.0-85003709715</pub-id>
<pub-id pub-id-type="pmid">27081657</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krab</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>de Goede-Bolder</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Aarsen</surname>
<given-names>F. K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial</article-title>
<source/>
<italic toggle="yes">The Journal of the American Medical Association</italic>
<year>2008</year>
<volume>300</volume>
<issue>3</issue>
<fpage>287</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1001/jama.300.3.287</pub-id>
<pub-id pub-id-type="other">2-s2.0-47549111338</pub-id>
<pub-id pub-id-type="pmid">18632543</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Vaart</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Plasschaert</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Rietman</surname>
<given-names>A. B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial</article-title>
<source/>
<italic toggle="yes">Lancet Neurology</italic>
<year>2013</year>
<volume>12</volume>
<issue>11</issue>
<fpage>1076</fpage>
<lpage>1083</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(13)70227-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-84885389443</pub-id>
<pub-id pub-id-type="pmid">24090588</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Douniol</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jacquette</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Guilé</surname>
<given-names>J. M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric and cognitive phénotype in children and adolescents with myotonic dystrophy</article-title>
<source/>
<italic toggle="yes">European Child and Adolescent Psychiatry</italic>
<year>2008</year>
<volume>18</volume>
<fpage>705</fpage>
<lpage>715</lpage>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Vries</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>P. F.</given-names>
</name>
</person-group>
<article-title>Genotype-phenotype correlations in tuberous sclerosis</article-title>
<source/>
<italic toggle="yes">Journal of Medical Genetics</italic>
<year>2000</year>
<volume>37</volume>
<issue>5</issue>
<fpage>e3</fpage>
<pub-id pub-id-type="doi">10.1136/jmg.37.5.e3</pub-id>
<pub-id pub-id-type="pmid">10807702</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Theoretical distribution of social responsiveness scale (SRS) scores in individuals with NF1 (<italic>n</italic> = 412).The admixture analysis shows that the best fitting model for SRS scores in NF1 founds 2 subgroups with low and high scores (mean SRS = 55 (red curve) and 70 (green curve), respectively). Data from Morris et al. [<xref ref-type="bibr" rid="B59">59</xref>].</p>
</caption>
<graphic xlink:href="CRIPS2019-4764031.001"></graphic>
</fig>
<table-wrap id="tab1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Clinical profile of NF1 patients with an intellectual deficiency.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1">Patient 1</th>
<th align="center" colspan="1" rowspan="1">Patient 2</th>
<th align="center" colspan="1" rowspan="1">Patient 3</th>
<th align="center" colspan="1" rowspan="1">Patient 4</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Sex, age</td>
<td align="center" colspan="1" rowspan="1">Male, 12 years</td>
<td align="center" colspan="1" rowspan="1">Male, 13 years</td>
<td align="center" colspan="1" rowspan="1">Male, 15 years</td>
<td align="center" colspan="1" rowspan="1">Female, 8 years</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Main reasons for referral</td>
<td align="center" colspan="1" rowspan="1">Increasing puberty-onset aggressiveness</td>
<td align="center" colspan="1" rowspan="1">ASD assessment</td>
<td align="center" colspan="1" rowspan="1">Psychiatric assessment in the context of sexual assault</td>
<td align="center" colspan="1" rowspan="1">Suspicion of ADHD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Suspicion of ADHD</td>
<td align="center" colspan="1" rowspan="1">Suspicion of ADHD</td>
<td align="center" colspan="1" rowspan="2">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Social problems (foster care)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Inpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">NF1 diagnosis</td>
<td align="center" colspan="1" rowspan="2">Familial NF1 (including intellectual disability)</td>
<td align="center" colspan="1" rowspan="1">Sporadic NF1</td>
<td align="center" colspan="1" rowspan="2">Familial NF1</td>
<td align="center" colspan="1" rowspan="2">Familial NF1</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Additional genetic research was negative: karyotype, x fragile</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="8">NF1 complications</td>
<td align="center" colspan="1" rowspan="1">Dystrophic thoracic scoliosis</td>
<td align="center" colspan="1" rowspan="1">Sphenoid bone dysplasia</td>
<td align="center" colspan="1" rowspan="7">Bilateral optic pathway tumor, remission</td>
<td align="center" colspan="1" rowspan="1">Optic pathway tumor, remission</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Sphenoid bone dysplasia</td>
<td align="center" colspan="1" rowspan="1">Orbicular-facial plexiform neurofibroma (surgically removed)</td>
<td align="center" colspan="1" rowspan="1">Precocious puberty</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Labile renovascular hypertension</td>
<td align="center" colspan="1" rowspan="6">UBOs<bold>:</bold> basal ganglia, cerebellum</td>
<td align="center" colspan="1" rowspan="1">Epilepsy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Intermittent claudication</td>
<td align="center" colspan="1" rowspan="5">UBOs: left pallidum, white matter</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Several complicated surgical interventions/hospitalisations</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Absence of pheocromocytoma or precocious puberty</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2">UBOs: bilateral temporal; right lentiform nucleus; cerebellum/protuberance</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Blindness</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Developmental delay (early history)</td>
<td align="center" colspan="1" rowspan="1">Vineland (age 4): developmental delays ranging from 7–39 months</td>
<td align="center" colspan="1" rowspan="1">Hypoxia at birth</td>
<td align="center" colspan="1" rowspan="2">?? (family poorly informative)</td>
<td align="center" colspan="1" rowspan="1">Prematurity</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">(Repeated gastroenteritis during childhood)</td>
<td align="center" colspan="1" rowspan="1">(Repeated gastroenteritis during childhood)</td>
<td align="center" colspan="1" rowspan="1">PEP-R (age 3): Average developmental delay 11–13 months</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Cognitive assessment</td>
<td align="center" colspan="1" rowspan="1">TERMAN–MERRILL</td>
<td align="center" colspan="1" rowspan="1">PEP-3: mild intellectual disability</td>
<td align="center" colspan="1" rowspan="6">Assessment not available</td>
<td align="center" colspan="1" rowspan="6">BRUNET-LEZINE (age 3): Developmental delays ranging from 8–14 months</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="5">Moderate intellectual disability</td>
<td align="center" colspan="1" rowspan="1">Divided attention TEA-Ch: −2.6SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Unimodal attention TEA-Ch −2.6SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Language EXALANG: delays in all domains (oral/written) (average: −1.7SD)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Flexibility NEPSY-II: −1.4SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Working memory NEPSY-II: −1.4SD</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">ASD assessment</td>
<td align="center" colspan="1" rowspan="1">CARS (age 4) = 30.5 (mild autism)</td>
<td align="center" colspan="1" rowspan="1">Clinical evaluation: repetitive behaviors and perseverant thoughts</td>
<td align="center" colspan="1" rowspan="4">No clinical suspicion</td>
<td align="center" colspan="1" rowspan="1">ADOS</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">ADI-R: stereotypies = 9 (threshold 3)</td>
<td align="center" colspan="1" rowspan="3">Deficits in social cognition/pragmatics: −1.3SD <sup>EMOTION COMPREHENSION TEST</sup></td>
<td align="center" colspan="1" rowspan="1">Communication domain = 6 (threshold 4)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Communication domain = 14 (threshold 8)</td>
<td align="center" colspan="1" rowspan="2">Social interaction = 14 (threshold 7)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Other: anxiety</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Psychiatric diagnosis</td>
<td align="center" colspan="1" rowspan="1">Moderate intellectual disability</td>
<td align="center" colspan="1" rowspan="1">Mild intellectual disability</td>
<td align="center" colspan="1" rowspan="5">Mild intellectual disability</td>
<td align="center" colspan="1" rowspan="1">Moderate intellectual disability</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Autism</td>
<td align="center" colspan="1" rowspan="1">Autism</td>
<td align="center" colspan="1" rowspan="1">Autism</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Dyspraxia</td>
<td align="center" colspan="1" rowspan="1">Dyspraxia</td>
<td align="center" colspan="1" rowspan="1">Dyspraxia</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">NF1 related stress (comorbidities)</td>
<td align="center" colspan="1" rowspan="2">ADHD-hyperkinetic type</td>
<td align="center" colspan="1" rowspan="1">NF1 related stress (comorbidities)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">No criteria for ADHD</td>
<td align="center" colspan="1" rowspan="1">ADHD-hyperkinetic type <sup>CONNERS; clinical assessment</sup></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="5">Medication</td>
<td align="center" colspan="1" rowspan="1">Aripiprazole</td>
<td align="center" colspan="1" rowspan="1">Methylphenidate</td>
<td align="center" colspan="1" rowspan="5">None</td>
<td align="center" colspan="1" rowspan="1">Levetiracetam</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Melatonin</td>
<td align="center" colspan="1" rowspan="4">Melatonin</td>
<td align="center" colspan="1" rowspan="1">Enantone</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Labetalol</td>
<td align="center" colspan="1" rowspan="1">Methylphenidate</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="2">Clonidine</td>
<td align="center" colspan="1" rowspan="1">Risperidone</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Melatonin</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Nonpharmacological treatment</td>
<td align="center" colspan="1" rowspan="1">Full time school for disabled adolescents, including remediation to improve attention, speech, motricity</td>
<td align="center" colspan="1" rowspan="1">Full time school for autistic adolescents</td>
<td align="center" colspan="1" rowspan="1">Full time school for disabled adolescents</td>
<td align="center" colspan="1" rowspan="1">Full time school for disabled children, including remediation to improve attention, speech, motricity.</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Regular follow-up</td>
<td align="center" colspan="1" rowspan="1">Adapted school activities, including remediation to improve attention</td>
<td align="center" colspan="1" rowspan="2">Regular psychiatric follow up</td>
<td align="center" colspan="1" rowspan="2">Foster family</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Regular multidisciplinary discussion</td>
<td align="center" colspan="1" rowspan="1">Speech remediation in the past</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Outcome</td>
<td align="center" colspan="1" rowspan="1">Clinical improvement</td>
<td align="center" colspan="1" rowspan="2">Stable</td>
<td align="center" colspan="1" rowspan="2">Improvement</td>
<td align="center" colspan="1" rowspan="1">Improvement (less than expected due to social difficulties)</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Balancing day-to-day life with the ongoing co-morbidities of NF1 is a challenge to him and his family</td>
<td align="center" colspan="1" rowspan="1">Balancing day-to-day life with the ongoing co-morbidities of NF1 is a challenge to her</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>ADHD, attention deficit hyperactivity disorder; ADI-R, autism diagnostic interview-Revised [<xref ref-type="bibr" rid="B15">15</xref>]; ADOS, autism diagnostic observation schedule [<xref ref-type="bibr" rid="B16">16</xref>]; ASD, autism spectrum disorder; BRUNET-LEZINE, First childhood psychomotor developmental schedule [<xref ref-type="bibr" rid="B18">18</xref>]; CARS, The childhood autistic rating scale [<xref ref-type="bibr" rid="B19">19</xref>]; CONNERS, Conner's continuous performance test [<xref ref-type="bibr" rid="B20">20</xref>]; EMOTION COMPREHENSION TEST, Test of emotion comprehension [<xref ref-type="bibr" rid="B27">27</xref>]; EXALANG, language evaluation for children 8–11 years [<xref ref-type="bibr" rid="B21">21</xref>]; NEPSY-II, Neuropsychological test for children [<xref ref-type="bibr" rid="B22">22</xref>]; NF1, Neurofibromatosis type 1; PEP, Psychoeducational profile: Revised (PEP-R) and third edition (PEP-3) [<xref ref-type="bibr" rid="B23">23</xref>]; TEA-Ch, test of everyday attention for children [<xref ref-type="bibr" rid="B24">24</xref>]; TERMAN-MERRILL, Stanford-Binet intelligence scale [<xref ref-type="bibr" rid="B25">25</xref>]; UBOs, unidentified bright objects; VINELAND, adaptive behaviour scales [<xref ref-type="bibr" rid="B28">28</xref>].</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tab2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Clinical profile of NF1 patients with subnormal IQ.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1">Patient 5</th>
<th align="center" colspan="1" rowspan="1">Patient 6</th>
<th align="center" colspan="1" rowspan="1">Patient 7</th>
<th align="center" colspan="1" rowspan="1">Patient 8</th>
<th align="center" colspan="1" rowspan="1">Patient 9</th>
<th align="center" colspan="1" rowspan="1">Patient 10</th>
<th align="center" colspan="1" rowspan="1">Patient 11</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Sex, age</td>
<td align="center" colspan="1" rowspan="1">Male, 10 years</td>
<td align="center" colspan="1" rowspan="1">Male, 8 years</td>
<td align="center" colspan="1" rowspan="1">Male, 8 years</td>
<td align="center" colspan="1" rowspan="1">Male, 9 years</td>
<td align="center" colspan="1" rowspan="1">Male, 15 years</td>
<td align="center" colspan="1" rowspan="1">Male, 7 years</td>
<td align="center" colspan="1" rowspan="1">Male, 12 years</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">Main reason for referral</td>
<td align="center" colspan="1" rowspan="1">Learning difficulties</td>
<td align="center" colspan="1" rowspan="1">Learning difficulties</td>
<td align="center" colspan="1" rowspan="1">Learning difficulties</td>
<td align="center" colspan="1" rowspan="1">Intermittent explosive behaviour; ADHD</td>
<td align="center" colspan="1" rowspan="1">Confirmation of ASD (ADOS-ADI-R)</td>
<td align="center" colspan="1" rowspan="1">Suspicion of ADHD</td>
<td align="center" colspan="1" rowspan="1">Mood disorder</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Anxiety symptoms</td>
<td align="center" colspan="1" rowspan="1">Behavioural difficulties</td>
<td align="center" colspan="1" rowspan="1">Hyperactivity sleep; family related issues</td>
<td align="center" colspan="1" rowspan="1">NF1 complications: Precocious puberty; nondysplastic scoliosis; UBOs: cerebellum, <italic>globus pallidus</italic></td>
<td align="center" colspan="1" rowspan="1">Emotional lability</td>
<td align="center" colspan="1" rowspan="1">NF1 related stress</td>
<td align="center" colspan="1" rowspan="1">Learning difficulties</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Social difficulties</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
<td align="center" colspan="1" rowspan="1">Outpatient unit</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NF1 diagnosis</td>
<td align="center" colspan="1" rowspan="1">Familial NF1</td>
<td align="center" colspan="1" rowspan="1">Familial NF1</td>
<td align="center" colspan="1" rowspan="1">Sporadic NF1</td>
<td align="center" colspan="1" rowspan="1">Sporadic NF1</td>
<td align="center" colspan="1" rowspan="1">Sporadic NF1</td>
<td align="center" colspan="1" rowspan="1">Sporadic NF1</td>
<td align="center" colspan="1" rowspan="1">Legius SD</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Developmental delay</td>
<td align="center" colspan="1" rowspan="1">Minor (graphic abilities)</td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Minor (global motor)</td>
<td align="center" colspan="1" rowspan="1">Walking unstable at 21 months</td>
<td align="center" colspan="1" rowspan="1">???</td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Not reported</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Repeated otitis</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Prematurity</td>
<td align="center" colspan="1" rowspan="1">Speech delay (Repeated otitis)</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Cognitive assessment WISC-IV</td>
<td align="center" colspan="1" rowspan="1">Verbal: 92; performance: 121; working memory: 97; speed: 88</td>
<td align="center" colspan="1" rowspan="1">Verbal: 86; performance: 77; working memory: 73; speed: 71</td>
<td align="center" colspan="1" rowspan="1">Verbal: 92; performance: 94; working memory: 76; speed: 78</td>
<td align="center" colspan="1" rowspan="1">Verbal: 98; performance: 65; working memory: 82; speed: 83</td>
<td align="center" colspan="1" rowspan="1">Verbal: 86; performance: 73; working memory: 109; speed: 100</td>
<td align="center" colspan="1" rowspan="1">Verbal: 92; performance: 109; working memory: 91; speed: 103</td>
<td align="center" colspan="1" rowspan="1">Verbal: 94; performance: 90; working memory: 73; speed: 66</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
<td align="center" colspan="1" rowspan="1">Heterogeneous</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Attention and executive functions</td>
<td align="center" colspan="1" rowspan="1">Divided attention <sup>TEA-Ch</sup>: −2SD</td>
<td align="center" colspan="1" rowspan="1">Divided attention <sup>TEA-Ch</sup>: −1.4SD</td>
<td align="center" colspan="1" rowspan="1">Divided attention <sup>TEA-Ch</sup>: Normal</td>
<td align="center" colspan="1" rowspan="1">Divided attention <sup>TEA-Ch</sup>: −0.5SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Divided attention <sup>TEA-Ch</sup>: +0.7SD</td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Unimodal attention <sup>TEA-Ch</sup>: Normal</td>
<td align="center" colspan="1" rowspan="1">Unimodal attention <sup>TEA-Ch</sup>: −1.4SD</td>
<td align="center" colspan="1" rowspan="1">Unimodal attention <sup>TEA-Ch</sup>: Normal</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Unimodal attention <sup>TEA-Ch</sup>: −0.7SD</td>
<td align="center" colspan="1" rowspan="1">Unimodal attention: <sup>TEA-Ch</sup> +0.3SD</td>
<td align="center" colspan="1" rowspan="1">Unimodal attention <sup>TEA-Ch</sup>: −0.7SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Sustained attention <sup>TEA-Ch</sup>: −1.7SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Attention control <sup>TEA-Ch</sup>: -2.2SD</td>
<td align="center" colspan="1" rowspan="1">Attention control <sup>TEA-Ch</sup>: +0.7SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Inhibition <sup>TEA-Ch</sup>: −2SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Inhibition <sup>TEA-Ch</sup>: +1SD</td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −0.1SD</td>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −1.5SD</td>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −0.5SD</td>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −1.5SD</td>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −1.4SD</td>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −0.1SD</td>
<td align="center" colspan="1" rowspan="1">Flexibility <sup>NEPSY-II</sup>: −0.2SD</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Memory</td>
<td align="center" colspan="1" rowspan="1">Short-term <sup>NEPSY-II</sup>: −0.1SD</td>
<td align="center" colspan="1" rowspan="1">Short-term <sup>NEPSY-II</sup>: −1.2SD</td>
<td align="center" colspan="1" rowspan="1">Short-term: −1.6SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Short-term <sup>NEPSY-II</sup>: −0.3SD</td>
<td align="center" colspan="1" rowspan="1">Short-term <sup>NEPSY-II</sup>: −0.7SD</td>
<td align="center" colspan="1" rowspan="1">Short-term <sup>NEPSY-II</sup>: −0.3SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Episodic<sup> REY</sup>: −0.3SD</td>
<td align="center" colspan="1" rowspan="1">Episodic<sup> REY</sup>: +0.5SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Episodic<sup> REY</sup>: +0.4SD</td>
<td align="center" colspan="1" rowspan="1">Episodic<sup> REY</sup>: −3SD</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="6">Language assessment EXALANG</td>
<td align="center" colspan="1" rowspan="1">Oral receptive: -0.7SD</td>
<td align="center" colspan="1" rowspan="1">Oral receptive: −1.5SD</td>
<td align="center" colspan="1" rowspan="1">Oral expressive: +1.4SD</td>
<td align="center" colspan="1" rowspan="1">Normal</td>
<td align="center" colspan="1" rowspan="1">Normal</td>
<td align="center" colspan="1" rowspan="1">Normal</td>
<td align="center" colspan="1" rowspan="1">Oral lexicon: −1.3SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Oral expressive: −0.5SD</td>
<td align="center" colspan="1" rowspan="1">Oral expressive: −2SD</td>
<td align="center" colspan="1" rowspan="1">Oral lexicon: −0.5SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Oral lexicon: +0.7SD</td>
<td align="center" colspan="1" rowspan="1">Oral lexicon: −1.2SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Written receptive: −2.6SD</td>
<td align="center" colspan="1" rowspan="1">Written expressive: −1.7SD</td>
<td align="center" colspan="1" rowspan="1">Written receptive: +1.4S</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Written expressive: −2.6</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Written expressive: −2.9SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Written expressive: −0.5SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Spelling: −2.6SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">Motricity</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: +0.5SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: Normal</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: −0.7SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: −3SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: −0.3SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: +0.2SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-construction<sup> REY</sup>: −0.7SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: +0.5SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: −0.6SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: −0.3SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: −0.1SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: −0.8SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: +0.3SD</td>
<td align="center" colspan="1" rowspan="1">Visuo-spatial <sup>NEPSY-II</sup>: −0.8SD</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Graphomotor skill<sup> BHK</sup>: −2.3SD</td>
<td align="center" colspan="1" rowspan="1">Graphomotor skill<sup> BHK</sup>: −2SD</td>
<td align="center" colspan="1" rowspan="1">Graphomotor skill<sup> BHK</sup>: −2SD</td>
<td align="center" colspan="1" rowspan="1">Graphomotor skill<sup> BHK</sup>: −2SD</td>
<td align="center" colspan="1" rowspan="1">Graphomotor skill<sup> BHK</sup>: +1.4SD</td>
<td align="center" colspan="1" rowspan="1">Graphomotor skill<sup> BHK</sup>: +0.4SD</td>
<td align="center" colspan="1" rowspan="1">Graphomotor skill <sup>BHK</sup>: −0.3SD</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Socio-cognition/pragmatic</td>
<td align="center" colspan="1" rowspan="1">−0.7SD</td>
<td align="center" colspan="1" rowspan="1">−0.3SD</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">−2.2SD</td>
<td align="center" colspan="1" rowspan="1">−1SD</td>
<td align="center" colspan="1" rowspan="1">Normal</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">Psychiatric Diagnosis</td>
<td align="center" colspan="1" rowspan="1">ADHD-inattentive type</td>
<td align="center" colspan="1" rowspan="1">
<italic>Borderline</italic> intelligence</td>
<td align="center" colspan="1" rowspan="1">Anxious disorder</td>
<td align="center" colspan="1" rowspan="1">
<italic>Borderline</italic> intelligence</td>
<td align="center" colspan="1" rowspan="1">ASD (Asperger)</td>
<td align="center" colspan="1" rowspan="1">Anxiety disorder</td>
<td align="center" colspan="1" rowspan="1">Mood disorder</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Dyslexia</td>
<td align="center" colspan="1" rowspan="1">ADHD-impulsive type</td>
<td align="center" colspan="1" rowspan="1">Motor (graphic) delay</td>
<td align="center" colspan="1" rowspan="1">ADHD, ODD</td>
<td align="center" colspan="1" rowspan="1">Dysexecutive profile</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Attachment disorder</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Pragmatic communication disorder</td>
<td align="center" colspan="1" rowspan="1">Dysexecutive profile</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Visual-Spatial Dyspraxia</td>
<td align="center" colspan="1" rowspan="1">Dyspraxia</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Written language difficulties</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">At risk for dyslexia</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Dysgraphia</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">NF1 related stress</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="2">Medication</td>
<td align="center" colspan="1" rowspan="2">Methylphenidate</td>
<td align="center" colspan="1" rowspan="2">Methylphenidate (not well tolerated)</td>
<td align="center" colspan="1" rowspan="2">Melatonin</td>
<td align="center" colspan="1" rowspan="1">Methylphenidate</td>
<td align="center" colspan="1" rowspan="2">Aripiprazole</td>
<td align="center" colspan="1" rowspan="2">None</td>
<td align="center" colspan="1" rowspan="2">Quetiapine</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Triptorelin Acetate</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="4">Nonpharmacological treatment</td>
<td align="center" colspan="1" rowspan="1">Specific school adaptations</td>
<td align="center" colspan="1" rowspan="1">Specific school adaptations</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Specific school adaptations</td>
<td align="center" colspan="1" rowspan="1">Specific school adaptations</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Speech and reading therapy</td>
<td align="center" colspan="1" rowspan="1">Speech and reading therapy</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Speech and reading therapy (past)</td>
<td align="center" colspan="1" rowspan="1">Language and motor remediation in the past</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Speech and reading therapy</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1">Motor skills remediation</td>
<td align="center" colspan="1" rowspan="1">Motor skills remediation</td>
<td align="center" colspan="1" rowspan="1">Motor skills remediation</td>
<td align="center" colspan="1" rowspan="1">Motor skills remediation</td>
<td align="center" colspan="1" rowspan="1">Social strategies group</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Psychotherapy</td>
<td align="center" colspan="1" rowspan="1">Psychodrama therapy</td>
<td align="center" colspan="1" rowspan="1"></td>
<td align="center" colspan="1" rowspan="1">Psychotherapy</td>
<td align="center" colspan="1" rowspan="1">Psychiatric follow-up</td>
</tr>
<tr>
<td align="left" colspan="8" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Outcome</td>
<td align="center" colspan="1" rowspan="1">Improvement</td>
<td align="center" colspan="1" rowspan="1">Improvement</td>
<td align="center" colspan="1" rowspan="1">Stable</td>
<td align="center" colspan="1" rowspan="1">Improvement</td>
<td align="center" colspan="1" rowspan="1">Stable</td>
<td align="center" colspan="1" rowspan="1">Stable</td>
<td align="center" colspan="1" rowspan="1">Stable</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>ADHD, attention deficit hyperactivity disorder; ADI-R, autism diagnostic interview-Revised [<xref ref-type="bibr" rid="B15">15</xref>]; ADOS, autism diagnostic observation schedule [<xref ref-type="bibr" rid="B16">16</xref>]; ASD, autism spectrum disorder; BHK, concise evaluation scale for children handwriting [<xref ref-type="bibr" rid="B17">17</xref>]; EMOTION COMPREHENSION TEST, Test of emotion comprehension [<xref ref-type="bibr" rid="B27">27</xref>]; EXALANG, language evaluation for children 8–11 years [<xref ref-type="bibr" rid="B21">21</xref>]; NEPSY-II, Neuropsychological test for children [<xref ref-type="bibr" rid="B22">22</xref>]; NF1, Neurofibromatosis type 1; ODD, oppositional defiant disorder; TEA-Ch, test of everyday attention for children [<xref ref-type="bibr" rid="B24">24</xref>]; REY, Rey's complex figure test [<xref ref-type="bibr" rid="B25">25</xref>]; UBOs, unidentified bright objects]; WISC IV, the Wechsler intelligence scale for children [<xref ref-type="bibr" rid="B29">29</xref>].</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>